| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Birmingham Veteran Affairs Medical Center and Division of Cardiovascular Disease, Department of Medicine, Vascular Biology and Hypertension Program, University of Alabama, Birmingham, Alabama 35294; and 2 Department of Anesthesia, University of Pennsylvania Health System, Philadelphia, Pennsylvania 19104
We utilized mice with homozygous
disruption of angiotensin-converting enzyme (ACE) (
/), mice with
heterozygous deletion of ACE (+/), and wild-type mice (+/+) to test
the hypothesis that genetic variation in ACE modulates tissue and
plasma angiotensin (ANG) II concentrations. With the use of ANG I as
substrate, kidney, heart, and lung ACE activity was reduced 80% in
/ mice compared with +/+ mice. However, ANG II concentrations and
ANG II-to-ANG I ratios in the kidney, heart, and lung did not differ
among genotypes. In contrast, plasma ANG II concentrations in /
mice were <2 fmol/ml, whereas plasma ANG I concentrations were
extremely high (765 fmol/ml). Chymase activity was increased 14-fold in
the kidney (P < 0.05) and 1.5-fold in the heart
(P < 0.05) of / versus +/+ mice but did not differ
among genotypes in the lung. ANG II formation from enzymes other than
ACE and chymase contributed <2% of total ANG II formation in all
genotypes. These data suggest that ACE is essential to ANG II formation
in the vascular space, whereas chymase may provide an important
mechanism in maintaining steady-state ANG II levels in tissue.
angiotensin I; chymase; angiotensin-converting enzyme
This article has been cited by other articles:
|
|
 |
|
  P. C. Cristovam, C. P. Arnoni, M. C. C. de Andrade, D. E. Casarini, L. G. Pereira, N. Schor, and M. A. Boim ACE-Dependent and Chymase-Dependent Angiotensin II Generation in Normal and Glucose-Stimulated Human Mesangial Cells Experimental Biology and Medicine, August 1, 2008; 233(8): 1035 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Garabelli, J. G. Modrall, J. M. Penninger, C. M. Ferrario, and M. C. Chappell Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart Exp Physiol, May 1, 2008; 93(5): 613 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. S. Evangelista and J. E. Krieger Small gene effect and exercise training-induced cardiac hypertrophy in mice: an Ace gene dosage study Physiol Genomics, November 21, 2006; 27(3): 231 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Fleming Signaling by the Angiotensin-Converting Enzyme Circ. Res., April 14, 2006; 98(7): 887 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Koka, W. Wang, X. R. Huang, S. Kim-Mitsuyama, L. D. Truong, and H. Y. Lan Advanced Glycation End Products Activate a Chymase-Dependent Angiotensin II-Generating Pathway in Diabetic Complications Circulation, March 14, 2006; 113(10): 1353 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Carter, G. Onder, S. B. Kritchevsky, and M. Pahor Angiotensin-Converting Enzyme Inhibition Intervention in Elderly Persons: Effects on Body Composition and Physical Performance J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2005; 60(11): 1437 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lundequist, E. Tchougounova, M. Abrink, and G. Pejler Cooperation between Mast Cell Carboxypeptidase A and the Chymase Mouse Mast Cell Protease 4 in the Formation and Degradation of Angiotensin II J. Biol. Chem., July 30, 2004; 279(31): 32339 - 32344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Modrall, J. Sadjadi, K. B. Brosnihan, P. E. Gallagher, C.-h. Yu, G. L. Kramer, K. E. Bernstein, and M. C. Chappell Depletion of Tissue Angiotensin-Converting Enzyme Differentially Influences the Intrarenal and Urinary Expression of Angiotensin Peptides Hypertension, April 1, 2004; 43(4): 849 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. McPherson, Z. Luo, R. A. Brown, L. S. LeBard, C. C. Corless, R. C. Speth, and S. P. Bagby Chymase-like Angiotensin II-Generating Activity in End-Stage Human Autosomal Dominant Polycystic Kidney Disease J. Am. Soc. Nephrol., February 1, 2004; 15(2): 493 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Husain, M. Li, and R. M. Graham Do Studies With ACE N- and C-Domain-Selective Inhibitors Provide Evidence for a Non-ACE, Non-Chymase Angiotensin II-Forming Pathway? Circ. Res., July 25, 2003; 93(2): 91 - 93. [Full Text] [PDF]
|
|
|
|
|
|
X. R. Huang, W. Y. Chen, L. D. Truong, and H. Y. Lan Chymase Is Upregulated in Diabetic Nephropathy: Implications for an Alternative Pathway of Angiotensin II-Mediated Diabetic Renal and Vascular Disease J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1738 - 1747. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
